

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

Zilretta (triamcinolone acetonide extended-release)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	One time

Medications	Quantity Limit
Zilretta 32mg (5 mL) injection	One injection (32 mg/5 mL) per knee per lifetime

APPROVAL CRITERIA

Requests for Zilretta (triamcinolone acetonide extended-release) may be approved if the following criteria are met:

- I. Individual has a diagnosis of osteoarthritis of the knee; **AND**
- II. Individual has not received previous administration of Zilretta to the requested knee; **AND**
- III. Individual has not received therapy with an intra-articular short-acting corticosteroid type drugs within the previous 3 months; **AND**
- IV. Individual has had a therapeutic failure, a contraindication, or is intolerant to all of the following (ACR 2017):
 - A. Non-pharmacological therapy, e.g. physical therapy; **AND**
 - B. Oral nonsteroidal anti-inflammatory drug (NSAID) at continuous therapeutic dosing (prescription strength); OR topical NSAID if unable to take oral NSAIDs; **AND**
 - C. Conventional injectable corticosteroids (e.g. immediate-release triamcinolone acetonide injection, methylprednisolone).

Requests for Zilretta may not be approved for the following:

- I. Individual is using for management of osteoarthritis pain of the shoulder, hip, or small joints, such as the hand; **OR**
- II. Individual is requesting repeat administration for the management of osteoarthritis pain of the knee; **OR**
- III. All other indications not included above.

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

Key References:

1. American College of Rheumatology (ACR). Osteoarthritis. Available at: <http://www.rheumatology.org>. Accessed July 22, 2020.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo- Controlled, Multinational Study. *The Journal of Bone and Joint Surgery American*. 2018;100(8):666-677.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 23, 2020.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
7. Kolasinski SL, Neogi T, Hochberg MC, et. al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care & Research*. 2020; 72 (2):149-162.
8. Zilretta [package insert]. Burlington, MA; Flexion Therapeutics, Inc; Jan 2020.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.